A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma

Mehta Vedant Kamal; Mahadev Rao; Rama Rao Damerla; Ananth Pai; Krishan Sharan; Akhil Palod; Preethi S. Shetty; Nawaz Usman; Naveena A.N. Kumar

doi:10.1080/07357907.2022.2139840

A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma

Mehta Vedant Kamal, Mahadev Rao, Rama Rao Damerla, Ananth Pai, Krishan Sharan, Akhil Palod, Preethi S. Shetty, Nawaz Usman, Naveena A.N. Kumar^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

Abstract

The combination of low-dose methotrexate and celecoxib as metronomic chemotherapy (MCT) is a novel therapy, believed to act by modulating the immune response, inhibiting angiogenesis and its cytotoxic action, though the exact mechanism of action is unclear. Clinically, MCT was found to be very effective in delaying tumor progression in patients with head and neck squamous cell carcinoma in both curative and palliative settings. This review was aimed to give a brief insight into the mechanism of action and potential molecular alterations of MCT in the treatment of oral cancers taking into consideration the various in vivo and in vitro studies.

Original language	English
Pages (from-to)	144-154
Number of pages	11
Journal	Cancer Investigation
Volume	41
Issue number	2
DOIs	https://doi.org/10.1080/07357907.2022.2139840
Publication status	Published - 2023

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/07357907.2022.2139840

Cite this

@article{a1dc9296da3243409c3128eb585536c1,

title = "A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma",

abstract = "The combination of low-dose methotrexate and celecoxib as metronomic chemotherapy (MCT) is a novel therapy, believed to act by modulating the immune response, inhibiting angiogenesis and its cytotoxic action, though the exact mechanism of action is unclear. Clinically, MCT was found to be very effective in delaying tumor progression in patients with head and neck squamous cell carcinoma in both curative and palliative settings. This review was aimed to give a brief insight into the mechanism of action and potential molecular alterations of MCT in the treatment of oral cancers taking into consideration the various in vivo and in vitro studies.",

author = "Kamal, {Mehta Vedant} and Mahadev Rao and Damerla, {Rama Rao} and Ananth Pai and Krishan Sharan and Akhil Palod and Shetty, {Preethi S.} and Nawaz Usman and Kumar, {Naveena A.N.}",

note = "Funding Information: All the images and illustrations were created with the help of BioRender (BioRender.com). Publisher Copyright: {\textcopyright} 2022 Taylor & Francis Group, LLC.",

year = "2023",

doi = "10.1080/07357907.2022.2139840",

language = "English",

volume = "41",

pages = "144--154",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma

AU - Kamal, Mehta Vedant

AU - Rao, Mahadev

AU - Damerla, Rama Rao

AU - Pai, Ananth

AU - Sharan, Krishan

AU - Palod, Akhil

AU - Shetty, Preethi S.

AU - Usman, Nawaz

AU - Kumar, Naveena A.N.

PY - 2023

Y1 - 2023

N2 - The combination of low-dose methotrexate and celecoxib as metronomic chemotherapy (MCT) is a novel therapy, believed to act by modulating the immune response, inhibiting angiogenesis and its cytotoxic action, though the exact mechanism of action is unclear. Clinically, MCT was found to be very effective in delaying tumor progression in patients with head and neck squamous cell carcinoma in both curative and palliative settings. This review was aimed to give a brief insight into the mechanism of action and potential molecular alterations of MCT in the treatment of oral cancers taking into consideration the various in vivo and in vitro studies.

AB - The combination of low-dose methotrexate and celecoxib as metronomic chemotherapy (MCT) is a novel therapy, believed to act by modulating the immune response, inhibiting angiogenesis and its cytotoxic action, though the exact mechanism of action is unclear. Clinically, MCT was found to be very effective in delaying tumor progression in patients with head and neck squamous cell carcinoma in both curative and palliative settings. This review was aimed to give a brief insight into the mechanism of action and potential molecular alterations of MCT in the treatment of oral cancers taking into consideration the various in vivo and in vitro studies.

UR - http://www.scopus.com/inward/record.url?scp=85141843271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141843271&partnerID=8YFLogxK

U2 - 10.1080/07357907.2022.2139840

DO - 10.1080/07357907.2022.2139840

M3 - Review article

C2 - 36269850

AN - SCOPUS:85141843271

SN - 0735-7907

VL - 41

SP - 144

EP - 154

JO - Cancer Investigation

JF - Cancer Investigation

IS - 2

ER -

A Mechanistic Review of Methotrexate and Celecoxib as a Potential Metronomic Chemotherapy for Oral Squamous Cell Carcinoma

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this